Le Lézard
Classified in: Health, Business
Subjects: EXE, AVO

Prime Therapeutics responds to safe harbor proposed rule on prescription drug rebates


EAGAN, Minn., Feb. 6, 2019 /PRNewswire/ -- Prime Therapeutics LLC (Prime), a leading pharmacy benefit manager (PBM) serving more than 27 million members nationally, released the following statement from Mike Kolar, its senior vice president and general counsel, in response to the Health and Human Services (HHS) Office of Inspector General's new safe harbor rule proposal to eliminate prescription drug rebates in Medicare Part D:

"We appreciate the Trump administration's desire to address high drug prices for consumers. Prime, too, is committed to being part of the solution to manage consumer out-of-pocket costs, and we work tirelessly every day to lower drug pricing through negotiations with pharmacies and manufacturers. In fact, we are the only leading PBM that is fully transparent with our clients, and whose business model is based upon a full pass through of rebate dollars as a means of controlling overall healthcare costs and premium rates for members.

One thing is clear ?pharmaceutical manufacturers alone set and raise prices. While we carefully review this proposal, our initial view is that this proposal doesn't do anything to mandate or encourage manufacturers to lower their list prices. As the rebate mechanism to help contain pharma's out-of-control price increases is eliminated, we encourage the development of alternate means that will ensure additional tools are available to put similar competitive pressure on manufacturers. This will continue to ensure that premiums and pharmacy counter costs are appropriately managed for beneficiaries.

Beyond the financial impact, the implementation date of Jan. 1, 2020 is highly concerning as bids for Medicare business are due June 1, 2019. This allows less than two months after comments to the rule are due for all PBMs, health plans, manufacturers and pharmacies to comply with the major changes that will be needed. We therefore urge the administration to proceed cautiously, take appropriate time and listen to all stakeholders, otherwise their actions could have unintended consequences for the most important stakeholder in this conversation ? the patient."

About Prime Therapeutics
Prime Therapeutics LLC (Prime) helps people get the medicine they need to feel better and live well. Prime manages pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid. The company processes claims and offers clinical services for people with complex medical conditions. Prime serves more than 27 million people. It is collectively owned by 18 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. For more information, visit www.primetherapeutics.com or follow @PrimePBM on Twitter.

Contact:

Karen Lyons, APR


Director of Public Relations


612.777.5742


klyons@primetherapeutics.com

 

SOURCE Prime Therapeutics LLC


These press releases may also interest you

at 00:01
T3D Therapeutics, a clinical stage drug development company engaged in the development of T3D-959 (the "Company"), a new orally administered treatment for Alzheimer's disease (AD), announced today that it has received a grant expected to total $9...

19 mai 2019
Victory Nutrition International Inc. ("VNI") announces results of a randomized, double-blind, placebo-controlled study for the Safety and Efficacy of N-SORBtm. This study is published in the Journal of American College of Nutrition (ACN), a highly...

19 mai 2019
Canada Pension Plan Investment Board's (CPPIB) wholly owned subsidiary CPPIB Credit Europe S.à r.l. has acquired a portion of LifeArc's royalty interests on worldwide sales of Keytruda®* (pembrolizumab) for approximately US$1.3 billion....

19 mai 2019
According to the new market research report "Vitamin D Market by Analog (Vitamin D2, Vitamin D3), Form (Dry, Liquid), Application (Functional Food & Beverage, Pharma, Feed, and Personal Care), End User (Children, Adult, and Pregnant Women), Iu...

19 mai 2019
Bridge Biotherapeutics Inc., a clinical-stage biotech company developing novel therapeutics for areas with high unmet medical needs, announced that the company presented interim data from a Phase I clinical study on BBT-877, a drug candidate for...

19 mai 2019
The Aesthetic Society announced the election of Charles H. Thorne, MD, a plastic surgeon practicing in New York City and Chairman of the Plastic Surgery Department at Lenox Hill Hospital, as the new President at the annual Aesthetic Meeting in New...



News published on 6 february 2019 at 12:00 and distributed by: